Atypical chronic myeloid leukemia, BCR-ABL1 negative
MONDO:0004653A myelodysplastic/myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene. (WHO, 2001)
Also known as: aCML, atypical CML, atypical chronic myeloid leukaemia, atypical chronic myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 Negative, subacute granulocytic leukaemia, subacute granulocytic leukemia, subacute myelogenous leukaemia
3086 clinical trials for this condition and its sub-types, 17 tagged with Atypical chronic myeloid leukemia, BCR-ABL1 negative itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a targeted drug boost chemo for hard-to-treat blood cancers?
Disease control OngoingThis phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Fitness test could guide safer stem cell transplants for seniors
Disease control OngoingThis study tests whether a geriatric assessment—looking at thinking, mobility, mood, nutrition, and medications—can help doctors choose the right transplant intensity for patients aged 60 and older with myeloid blood cancers. The goal is to reduce deaths from transplant complicat…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Promising blood cancer combo trial pulled before it even started
Disease control CancelledThis early-stage trial aimed to test a combination of two drugs—ASTX727 (already approved for some blood cancers) and ASTX029 (an experimental ERK inhibitor)—in adults with myelodysplastic syndromes (MDS) or related blood cancers that have a mutation in the RAS pathway. The goal …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could your phone camera replace blood tests? new study explores
Knowledge-focused OngoingThis study follows 60 people with lower-risk myelodysplastic neoplasms (MDS) who need regular red blood cell transfusions. Over 6 months, participants use a smartphone app to answer weekly quality-of-life questions and take photos of their fingernails or eyelids. Researchers aim …
Sponsor: University of Leipzig • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC